These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36695797)

  • 1. THE REPORTING QUALITY OF NONINFERIORITY TRIALS USING INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS.
    Jia H; Li T; Wan H; Wu Z; Sun X
    Retina; 2023 Feb; 43(2):243-253. PubMed ID: 36695797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.
    Bikdeli B; Welsh JW; Akram Y; Punnanithinont N; Lee I; Desai NR; Kaul S; Stone GW; Ross JS; Krumholz HM
    Circulation; 2019 Jul; 140(5):379-389. PubMed ID: 31177811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.
    Gyawali B; Tessema FA; Jung EH; Kesselheim AS
    JAMA Netw Open; 2019 Aug; 2(8):e199570. PubMed ID: 31469391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methodological and Reporting Quality of Noninferiority Randomized Controlled Trials Comparing Antibiotic Therapies: A Systematic Review.
    Bai AD; Komorowski AS; Lo CKL; Tandon P; Li XX; Mokashi V; Cvetkovic A; Kay VR; Findlater A; Liang L; Loeb M; Mertz D
    Clin Infect Dis; 2021 Oct; 73(7):e1696-e1705. PubMed ID: 32901800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting.
    Dekkers OM; Cevallos M; Bührer J; Poncet A; Ackermann Rau S; Perneger TV; Egger M
    J Clin Epidemiol; 2015 May; 68(5):510-7. PubMed ID: 25450451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.
    Morshedi RG; Ricca AM; Wirostko BM
    J Glaucoma; 2016 Mar; 25(3):291-300. PubMed ID: 25318578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reporting of noninferiority and equivalence randomized trials for major prostaglandins: a systematic survey of the ophthalmology literature.
    Eyawo O; Lee CW; Rachlis B; Mills EJ
    Trials; 2008 Dec; 9():69. PubMed ID: 19055743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ensuring Superior Reporting of Radiation Therapy Noninferiority Trials: A Systematic Review.
    Arifin AJ; Tan VS; Yan M; Warner A; Boldt RG; Chen H; Rodrigues GB; Palma DA; Louie AV
    Adv Radiat Oncol; 2023; 8(3):101178. PubMed ID: 36852015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
    Smith JM; Steel DH
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD008214. PubMed ID: 26250103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Issues in Conduct and Reporting of Noninferiority Randomized Controlled Trials in Surgical Management of Cancer Patients.
    Parsyan A; Marini W; Fazelzad R; Moher D; McCready D
    Ann Surg Oncol; 2021 Jan; 28(1):39-47. PubMed ID: 32430749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.